Larissa Estessi de Souza,Chiara Maria Righini,Dimitri Brigide de Almeida Mantovani et al.
Larissa Estessi de Souza et al.
Purpose: This work aimed to monitor the Down Syndrome Ts65Dn animal model across lifespan to detect time-dependent in vivo molecular alterations that may be associated with neurodegeneration and neuroinflammation in this ...
Unravelling the role of L- and D- alanine in prostate cancer: a Positron Emission Tomography study in a genetic mouse model [0.03%]
L-和D-丙氨酸在前列腺癌中的作用：基因型小鼠模型中的正电子发射断层扫描研究
Pilar Castellnou,María Gómez-Martínez,Vanessa Gómez-Vallejo et al.
Pilar Castellnou et al.
Introduction: Cancer cells often exhibit aberrant cellular metabolism, with a common characteristic being their reliance on anaerobic glucose utilization. Prostate cancer (PC), however, displays unique metabolic profiles ...
Anoushka Sachdeva,Jyotsna Bhatt Mitra,Archana Mukherjee
Anoushka Sachdeva
Ubiquicidin (UBI), a 59-amino-acid protein, demonstrates potent antimicrobial activity against various microorganisms and has been proposed as a potential antimicrobial agent. Similar to other antimicrobial proteins and peptides (AMPs), UBI...
Philipp Mohr,Joyce van Sluis,Adrienne H Brouwers et al.
Philipp Mohr et al.
Purpose: Clinical 89Zr-immunoPET relies on semi-quantitative metrics, such as standardised uptake values (SUV) from static imaging at delayed time points. However, SUV can misinterpret target engagement as it ignores plas...
Corrigendum to "radiation dosimetry of the 18 kDa translocator protein ligand [18F]PBR111 in humans" [nuclear medicine and biology, 144-145 (2025); 109,011] [0.03%]
“[18F]PBR111 标记小分子配体的人体内 18 kDa 转位蛋白放射剂量学研究”一文的勘误页（刊载于核医学与生物学，2025 年，144-145 期；2022 年，109,011）
Benjamin B Tournier,Zahra Mansouri,Yazdan Salimi et al.
Benjamin B Tournier et al.
Theranostic nanoparticles: Investigation of superparamagnetic iron oxide nanoparticles intrinsically labeled with Zirconium-89 and Actinium-225 [0.03%]
本征放射性标记的超顺磁氧化铁纳米颗粒的诊疗应用及研究
George Diehl,Zane G Archibald,Katherine Gingrich et al.
George Diehl et al.
Superparamagnetic iron oxide nanoparticles (SPIONs) are of interest for use as drug delivery vehicles due to their magnetic properties, tunable surface chemistry, and potential for use in magnetic resonance imaging and hyperthermia studies....
[18F]BCPP-BF-PET as an imaging tool for mitochondrial dysfunction in diabetic pancreatopathy and nephrotoxicity [0.03%]
[18F]BCPP-BF正电子发射断层扫描用于糖尿病胰病和肾毒性的线粒体功能障碍成像工具
Yuki Tomonari,Masakatsu Kanazawa,Shingo Nishiyama et al.
Yuki Tomonari et al.
Purpose: [18F]BCPP-BF-PET imaging of mitochondrial complex I was validated as a biomarker of hyperglycaemia- and hyperlipidaemia-induced pancreatic and renal dysfunction in a type 2 diabetes mellitus (T2DM) animal model. ...
Radiobiological effect of alpha particles. The scientific basis of targeted alpha-particle therapy [0.03%]
α粒子的放射生物学效应及靶向α粒子治疗的科学依据
Pedro Cruz-Nova,Maydelid Trujillo-Nolasco,Liliana Aranda-Lara et al.
Pedro Cruz-Nova et al.
Targeted alpha therapy (TAT) uses alpha-emitting radionuclides to deliver high-energy radiation directly to a specific biological target. TAT has shown promising results in the treatment of advanced metastatic disease and has demonstrated g...
Trithiol ligand provides tumor-targeting 191Pt-complexes with high molar activity and promising in vivo properties [0.03%]
三硫醇配体提供高摩尔活性和有前景的体内性质的肿瘤靶向191Pt复合物
Honoka Obata,Atsushi B Tsuji,Yutian Feng et al.
Honoka Obata et al.
Purpose: The Auger electron-emitting radionuclide 191Pt is a promising candidate for radiopharmaceutical therapy. Herein, we explored novel labeling methods for 191Pt using thiol-containing ligands to improve the in vivo ...
A novel synergistic drug combination of a mitogen-activated extracellular signal-regulated kinase inhibitor with [177Lu]Lu-rhPSMA-10.1 for prostate cancer treatment: Results of a preclinical evaluation [0.03%]
一种针对前列腺癌治疗的新型协同药物组合：细胞外信号调节激酶抑制剂与[177Lu]Lu-rhPSMA-10.1的结合：一项临床前评估的结果
Caroline Foxton,Bart Cornelissen,Edward O&#x;Neill et al.
Caroline Foxton et al.
Purpose: The prostate-specific membrane antigen (PSMA)-targeted radiohybrid ligand [177Lu]Lu-rhPSMA-10.1 is a promising next-generation radiopharmaceutical therapy in prostate cancer. This preclinical evaluation comprised...